Click on the links below to preview selected pages from this course.
- Individualized Medicine
- Polymorphism and CYP450
- Enzyme Abnormalities and Drugs
- Clinical Utility
- Warfarin Metabolism
- Warfarin Metabolism, continued
- A person who is classified as an ultrarapid metabolizer (UM) would need __________ of a drug metabolized by that enzyme.
- CYP450 Induction and Inhibition
- CYP450 Induction and Inhibition, continued
- A patient is taking cimetidine for a stomach ulcer. This drug inhibits CYP2D6. The patient is now prescribed amphetamine for narcolepsy. Amphetamine i...
- Genotype versus Phenotype
- Genotype versus Phenotype, continued
- TDM and PGx
- The Bottom Line
- The Bottom Line, continued
Level of instruction: Intermediate
Intended Audience: Clinical laboratory technologists and technicians as well as other health care personnel who are responsible for prescribing and administering therapeutic medications.
Author Credentials: Kevin F. Foley, PhD, DABCC, MT, SC is the director of clinical pathology for the Kaiser Permanente Northwest region. He also teaches clinical chemistry at Oregon Health Sciences University. Dr. Foley earned his PhD in clinical pharmacology and toxicology at East Carolina School of Medicine in North Carolina. He received a PhD in clinical pharmacology and toxicology from Brody School of Medicine, Greenville, NC. He has been working in laboratory medicine for over 15 years, starting his career as a medical technologist.
Reviewer Credentials: Robert E. Moore, MLS(ASCP)CM, SCCM, TC(NRCC) is the lead technologist in the toxicology laboratory at Kaiser Permanente in Portland, Oregon where his responsibilities include methods development and validation, review of QC data, instrument troubleshooting, and employee training/competency assessment. In his career as a medical laboratory scientist, he has been a chemistry supervisor, toxicology supervisor, and laboratory director. He holds a Bachelors degree in Biology from Marshall University.